IDEXX Laboratories, Inc. (IDXX)

In August 2025, IDEXX raised its full-year profit and revenue forecasts after better-than-expected second-quarter results, leading to an 8% rise in premarket trading. In November 2025, the stock reached an all-time high closing price of $766.68. In February 2026, Q4 2025 revenue exceeded forecasts, but EPS slightly missed expectations, causing a pre-market stock decline. The company's initial 2026 guidance was perceived as cautious.

Demand for IDEXX Laboratories' products and services exhibits seasonality, particularly in veterinary care. Spring may bring an increase in patients requiring parasite prevention. Summer can see a slowdown as families travel. Winter might lead to increased demand for indoor pet care and the management of chronic conditions. Recurring revenue streams and international adoption of water safety standards help to provide stable demand across its segments.

IDEXX Laboratories, Inc. is a global leader in pet healthcare innovation, operating in diagnostics and research. It develops, manufactures, and distributes diagnostic products, equipment, and services for companion animal veterinary, livestock and poultry, water testing, and dairy markets. Key offerings include in-clinic diagnostics, reference laboratory services, veterinary software solutions, and water testing solutions.

IDEXX Laboratories has a significant global presence, serving customers in over 175 countries and territories. It maintains a leading presence in North America and is expanding in Europe, Asia-Pacific, and Latin America through direct sales and distributor networks.

IDEXX Laboratories maintains a strong brand reputation as a global leader in pet healthcare innovation. The company is recognized for its consistent innovation and comprehensive product offerings. The successful launch of IDEXX Cancer Dx™ and adoption of IDEXX inVue Dx have contributed to its reputation. The company's focus on expanding its instrument and software installed bases and a strong innovation pipeline further bolster its standing.

IDEXX Laboratories, Inc. is primarily held by institutional investors, who own approximately 59.37% of the company's stock. Insiders hold 0.28%, and public companies and individual investors hold 40.35%. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., State Street Corp, Fundsmith LLP, and Capital Research Global Investors.